Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells

Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00770523

Enrollment

Registered

2008-10-10

Start date

2003-12-31

Completion date

2008-12-31

Last updated

2011-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HEMATOLOGIC MALIGNANCIES

Keywords

patients without comorbidity

Brief summary

Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients with Hematologic Malignancies.

Detailed description

Primary end points are treatment-related mortality and engraftment. Secondary end points are regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 55 Years

Healthy volunteers

Inclusion criteria

-Patients should have an unrelated donor who is matched for HLA-A and -B by serology and for -DRB1 by molecular typing.

Exclusion criteria

* Patients should not have major illness or organ failure * Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible. * Patients must not be pregnant or lactating.

Design outcomes

Primary

Measure	Time frame
treatment-related mortality and engraftment	all cause mortality

Secondary

Measure	Time frame
regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.	Time point(s) at which outcome measure is assessed.

Countries

South Korea

Outcome results